Affirms 2025 revenue outlook $415M-$425M, consensus $420.83M. The company said, “Our first quarter performance reflected strong commercial execution from our team across software and services. Despite the challenges facing our customers in the biopharma industry, we are reiterating guidance for 2025.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara reports Q1 adjusted EPS 14c, consensus 11c
- CERT Upcoming Earnings Report: What to Expect?
- Certara price target raised to $18 from $15 at KeyBanc
- Certara’s Hold Rating: Balancing Short-term Resilience with Long-term Regulatory Opportunities
- Certara’s Balanced Outlook: Hold Rating Amid Mixed Signals of Growth and Risk